



1301 E. Arapaho Rd., Ste. 101  
Richardson, TX 75081

This prescription form is to be sent & received via fax

**Dermatologic  
Oncology  
Enrollment Form**

Physician Offices Call:  
855-460-7928

Fax: 855-662-6779

<b>Prescriber:</b>		<b>NPI:</b>
<b>Supervising Physician:</b>		<b>NPI:</b>
Address:		<b>Tax ID:</b>
Phone:	Fax:	
Contact:		

**PATIENT INFORMATION**

Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State:	ZIP:
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____

**PRESCRIPTION**

<input type="checkbox"/> New <input type="checkbox"/> Refill	Ship by: ____/____/____	SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____
Drug	Directions & Quantity	Refills
Erivedge® <input type="checkbox"/> 150 mg Capsules	<input type="checkbox"/> Take 150 mg once daily by mouth (Quantity: 28)	
Odomzo® <input type="checkbox"/> 200 mg Capsules	<input type="checkbox"/> Take 200 mg once daily by mouth on an empty stomach, at least 1 hour before or 2 hours after a meal (Quantity: 30)	
Targretin® (bexarotene) <input type="checkbox"/> 75 mg Capsules BSA Required: _____ m <sup>2</sup>	<input type="checkbox"/> Take _____ mg by mouth once daily with food (Quantity: QS 30 days) <b>***RECOMMENDED DOSING*** 300 mg/m<sup>2</sup>/day-taken as one daily dose</b>	
Targretin® <input type="checkbox"/> 1% Gel 60 gm	INITIAL: Quantity: 1 tube <input type="checkbox"/> Week 1: Apply to affected area(s) once every <b>other</b> day as directed <input type="checkbox"/> Week 2: Apply to affected area(s) once daily as directed <input type="checkbox"/> Week 3: Apply to affected area(s) twice daily as directed <input type="checkbox"/> Week 4: Apply to affected area(s) three times daily as directed <input type="checkbox"/> Week 5: Apply to affected area(s) four times daily as directed MAINTENANCE: <input type="checkbox"/> Apply to affected area(s) _____ times daily as directed (Quantity: 1 tube)	

**MEDICAL INFORMATION**

**\*\*\*PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY\*\*\***

Previous Therapies:	Tried & Failed (Duration):	Not Tolerated:	Reason(s) for Discontinuing:
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____

<p><b>Erivedge®</b></p> <p>Please specify patient as: <input type="checkbox"/> locally advanced disease <input type="checkbox"/> metastatic disease</p> <p><input type="checkbox"/> Patient has basal cell carcinoma that has recurred following surgery</p> <p><input type="checkbox"/> Patient has basal cell carcinoma and is <i>not</i> a candidate for surgery and <i>not</i> a candidate for radiation</p>	<p><b>Odomzo®</b></p> <p><input type="checkbox"/> Patient has locally advanced basal cell carcinoma that has recurred following surgery</p> <p><input type="checkbox"/> Patient has locally advanced basal cell carcinoma and is <i>not</i> a candidate for surgery and <i>not</i> a candidate for radiation</p>
--	--

<p>Date of Diagnosis: ____/____/____</p> <p><input type="checkbox"/> C44.91 Basal cell carcinoma, unspecified</p> <p><input type="checkbox"/> C84.A0 Cutaneous T-cell lymphoma, unspecified, unspecified site</p> <p><input type="checkbox"/> Other: _____</p>	<p><input type="checkbox"/> C44.____</p> <p><input type="checkbox"/> C84.A____ Cutaneous T-cell lymphoma, unspecified, _____</p>	<p><b>Allergies:</b></p>
--	--	--------------------------

Additional Clinical Information:

**PRESCRIBER SIGNATURE REQUIRED---STAMPED SIGNATURE NOT ALLOWED**

**To Prescriber:** By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

PRODUCT SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

X \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ X \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

**CONFIDENTIALITY NOTICE**

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.